Skip to main content

Table 2 Factors associated with relapse during the 24 months of follow-up in the multivariate Cox proportional-hazards models: Adjusted Hazard Ratio (HR) and its corresponding 95% confidence interval (95% CI)

From: Quality of life is predictive of relapse in schizophrenia

  SF-36 Model QoLI Model
  HR 95% IC p-value HR 95% IC p-value
Quality of life
SF36 - Physical Composite Score * 0.82 (0.74;0.91) p < 0.001 - - -
SF36 - Mental Composite Score ** 0.88 (0.81;0.96) p = 0.002 - - -
QoLI - OLS score*** - - - 0.91 (0.81;1.01) p = 0.083
Socio-demographic characteristics
Age 0.98 (0.98;0.99) p = 0.001 0.98 (0.98;0.99) p < 0.001
Gender (Male) 1.06 (0.88;1.30) p = 0.532 1.12 (0.93;1.34) p = 0.249
Severity of symptoms: PANSS1
Positive PANSS score 0.99 (0.97;1.02) p = 0.514 0.99 (0.97;1.02) p = 0.560
Negative PANSS score 1.01 (0.99;1.03) p = 0.248 1.00 (0.98;1.02) p = 0.969
General Psychopathology PANSS score 0.99 (0.97;1.01) p = 0.419 1.00 (0.98;1.02) p = 0.937
Functioning
GAF2 0.98 (0.97;0.99) p < 0.001 0.98 (0.97;0.99) p < 0.001
Side Effects
BAS3 0.99 (0.95;1.02) p = 0.497 1.00 (0.97;1.03) p = 0.844
Medication
Second-generation antipsychotics (Yes) 1.07 (0.88;1.29) p = 0.508 1.13 (0.94;1.36) p = 0.195
Attitude towards medication: ROMI4
ROMI compliance score 0.97 (0.94;0.99) p = 0.041 0.97 (0.95;1.00) p = 0.063
  1. 1 Positive and Negative Syndrome Scale; 2Global Assessment Functioning; 5Barnes Akathisia score; 4Rating of Medication Influences Scale.
  2. * HR for the SF36 - Physical Composite Score should be interpreted this way, “an increase of 10 points on the Physical Composite Score multiplied by 0.82 the instantaneous risk of relapse at 24 months”;
  3. ** HR for the SF36 - Mental Composite Score should be interpreted this way, “an increase of 10 points on the Mental Composite Score multiplied by 0.88 the instantaneous risk of relapse at 24 months”;
  4. *** HR for the QoLI - OLS score should be interpreted this way, “an increase of 1 point on the QoLI score multiplied by 0.91 the instantaneous risk of relapse at 24 months”.